Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumorsAshlyn Parkhurst, Jeffrey Rubens, Sabrina Wang et al.|Cell Death and Disease|2022Cited by 8
ATRT-26. The PI3k inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumorsTyler Findlay, Jeffrey Rubens, Kristen Malebranche et al.|Neuro-Oncology|2022Cited by 3
Abstract 6498: MEK inhibitor mirdametinib suppresses MAP kinase pathway activity and inhibits tumor growth in atypical teratoid/rhabdoid tumorsYiming Deng, Eric H. Raabe, Kristen Malebranche et al.|Cancer Research|2024Cited by 1
ATRT-17. INHIBITING THE MAP KINASE PATHWAY WITH MEK INHIBITOR MIRDAMETINIB SUPPRESSES CANCER GROWTH IN ATYPICAL TERATOID/RHABDOID TUMORSYiming Deng, Eric H. Raabe, Kristen Malebranche et al.|Neuro-Oncology|2024Cited by 1
ATRT-15. COMBINING THE PI3K INHIBITOR PAXALISIB WITH NUCLEOSIDE ANALOG GEMCITABINE TO IMPROVE SURVIVAL OF ATYPICAL TERATOID/RHABDOID TUMORSTyler Findlay, Eric H. Raabe, Kristen Malebranche et al.|Neuro-Oncology|2024Cited by 1